Andrew Twiggy Forrest buys 5 mill worth, page-35

How long is a piece of string!

The FiftyOne Capital podcast indicates they expect it could be taken before the P3 trial even commences.

I think a good indication will come from who they pick to complete the manufacture and supply agreement with (Q3). If it is AstraZeneca then I dunno could be quite swift like FiftyOne Capital has indicated.

If you read the recent presentation and was announced earlier, they have engaged the Ex AstraZeneca team who developed Exanetide to complete the re purposing for Presendin...

But alas big Pharma also have no issues with paying overs at a later date as long as they know it works, they pay double or triple it's not an issue.

Jason Loveridge is a specialist at offloading companies for takeovers as well, hence why he was put here.

Probably doesn't really answer your question but could it happen before P3...most other biotech companies I'd say no. But given this is a re purposed and orphan drug which has met solid endpoints plus the original drug is manufactured by a big pharma...yeah potentially they may just take it early.

So I guess it's just if you wanna take the risk of seeing if we get to the P3 trial or if you think it could go earlier. Either way it will be well north of where the price is at the moment IMO.